Short reports

Haemoglobin O Padova and falsely low haemoglobin A_{1c} in a patient with type I diabetes

W J Schnedl, E C Reisinger, S Katzensteiner, R W Lipp, F Schreiber, P Hopmeier, G J Krejs

Abstract

Glycated haemoglobin (HbA_{1c}) measured by high performance liquid chromatography (HPLC) in a 20 year old female with insulin dependent diabetes mellitus was consistently within the normal range although her daily blood glucose values were > 11.1 mmol/l. HbA_{1c} measured by immunoagglutination and fructosamine was elevated and correlated with the patient's blood glucose values. The HPLC chromatogram showed an additional peak at HbA₀. Electrophoresis of haemoglobin on citrate agar gel revealed an abnormal haemoglobin anodal of HbS. Cellulose acetate electrophoresis and isoelectric focusing demonstrated an additional haemoglobin migrating close to HbA₂. Amino acid analysis and DNA sequencing revealed an α 30 (B11) Glu→Lys replacement, that is, haemoglobin O Padova. Investigations of two family members without diabetes revealed the same rare haemoglobin variant. This case showed that this silent haemoglobin mutation caused an additional peak and falsely low HbA_{1c} values when measured by HPLC, the gold standard for this evaluation. (J Clin Pathol 1997;50:434-435)

Keywords: high performance liquid chromatography; haemoglobin variants; insulin dependent diabetes mellitus

A 20 year old white female patient with insulin dependent diabetes mellitus treated with insulin, presented to the diabetes outpatient clinic of the department of internal medicine at Karl Franzens University, Graz, Austria. The glycated haemoglobin (HbA_{1c}) measurement of 6.2% measured with high performance liquid chromatography (HPLC) (Diamat, Bio-Rad, Vienna, Austria) was just above the upper limit of normal (4.2-6.1%) (fig 1) and suggested good blood glucose control. Her mean blood glucose concentration was elevated at 12.4 mmol/l (mean of four to five daily home measurements during one week before HbA_{1c} evaluation), her HbA_{1c} measured by latex immunoassay (DCA 2000, Bayer, Vienna, Austria) was 8.9% (normal 4.5-5.7%), and serum fructosamine was also elevated to 398 μ mol/l (normal < 285 μ mol/l).

Figure 1 HPLC chromatogram and haemoglobin report of a patient with insulin dependent diabetes mellitus with haemoglobin O Padova. HbA_{1a} 0.4%; HbA_{1b} 0.6%; HbF 0.1%; HbA_{1c} 6.2%; HbA₀ 73.1%; peak 6, 19.7%.

Investigation of two family members without diabetes revealed haemoglobin O Padova values of 4.7% with HPLC, and 5.3% and 5.2% with immunoagglutination. Their serum fructosamine was in the normal range. Routine haematological indices and all other parameters were normal in all three family members.

Electrophoretic analysis of a blood sample from the patient with diabetes on cellulose acetate membranes (Helena Laboratories, Beaumont, Texas, USA) using Tris EDTA borate buffer at pH 8.4¹ revealed an abnormal haemoglobin migrating very close to HbA₂, the two variants accounting for 24% of total haemoglobin.² Citrate agar electrophoresis of haemoglobin using citrate buffer at pH 6.2 demonstrated an additional haemoglobin slightly anodal of HbS.³ Isoelectric focusing on commercial gel plates revealed a haemoglobin close to HbA₂. Quantification of HbA₂ with a cation exchange chromatography kit (Haemoglobin Testing System, β -Thalassemia Short

Department of Internal Medicine,
Karl Franzens University, Graz,
Austria

W J Schnedl
E C Reisinger
S Katzensteiner
R W Lipp
F Schreiber
G J Krejs

Central Laboratory,
City Hospital Rudolfstiftung, Vienna,
Austria
P Hopmeier

Correspondence to:
Dr Wolfgang J Schnedl,
Department of Internal
Medicine, Karl Franzens
University, Auenbruggerplatz
15, A-8036 Graz, Austria.

Accepted for publication
3 February 1997

Program, Bio-Rad) showed 1.8% HbA₂ and 20.2% abnormal haemoglobin. Amino acid analysis of isolated tryptic peptides and sequence analysis of amplified DNA⁴ revealed an α 30 (B11) Glu→Lys mutation identical to that described for the silent haemoglobin variant O Padova.^{2,5} A heat stability test did not reveal unstable haemoglobins. HbF and the intracellular distribution of HbF were normal. Heinz bodies and HbH inclusion bodies⁴ were not found.

Conclusions

We report the case of a 20 year old female patient with insulin dependent diabetes and two of her family members, all bearing the rare silent haemoglobin variant O Padova. The haemoglobin variant caused falsely low HbA_{1c} measurements and an additional peak in the HPLC chromatogram (fig 1) in the patient with diabetes.

There are several methods available for HbA_{1c} determination.⁶ HPLC with cation exchange columns was recently selected to be the reference for HbA_{1c} measurement with which other methods are to be compared.⁷ Using this HPLC method, the O Padova peak seems to be included in the total peak calculation, thereby falsely lowering the HbA_{1c} value.

Periodic measurement of HbA_{1c} validates the accuracy of home blood glucose measurements of patients with intensified insulin therapy. The Diabetes Control and Complications Trial predicted an increase in the number of glycohaemoglobin tests.⁸ A deviation of 1% in HbA_{1c} reflects a change of about 1.4–1.9 mmol/l in average blood glucose; therefore, HbA_{1c} is highly sensitive to blood glucose elevations. Glycohaemoglobin more than 3% above the normal limit indicates mean blood glucose levels of more than 11.1 mmol/l during the three months before investigation.⁶ Other factors that can alter the charge of haemoglobin and influence glycohaemoglobin results include uraemia,⁹ alcohol dependence,¹⁰ and high doses of aspirin.¹¹ HbF levels are elevated in some diabetic patients and this may lead to inappropriately high HbA_{1c} results.¹²

If the clinical impression and HbA_{1c} results do not match in the case of repeatedly inappropriate HbA_{1c} or additional peaks in HPLC chromatograms, the HbA_{1c} values must be determined with a second method such as immunoagglutination.¹³ Blood glucose measurements and fructosamine results are not always well correlated,¹⁴ therefore, correct HbA_{1c} values and mean blood glucose are the most appropriate methods, but only if the contribution of variant haemoglobins are properly accounted for.

HPLC has been shown to separate several haemoglobin variants. Some variants cause excessively high HbA_{1c} values.¹⁵ Haemoglobinopathies such as haemoglobin C and S may falsely lower glycohaemoglobin values.¹⁶ α chain haemoglobin variants lead to either under or over estimation of HbA_{1c},¹⁷ and may cause additional single peaks or, as in the present report, a peak that overlaps with the HbA₀ peak.

We conclude that haemoglobin O Padova can contribute to mismanagement of patients with insulin dependent diabetes mellitus because of falsely low HbA_{1c} measured by HPLC.

The authors thank Dr THJ Huisman and his associates at the Department of Biochemistry and Molecular Biology, Medical College of Georgia, Augusta, Georgia, USA, for sequencing haemoglobin O Padova.

- Briere RO, Golias T, Batsakis JG. Rapid qualitative and quantitative hemoglobin fractionation: cellulose acetate electrophoresis. *Am J Clin Pathol* 1965;44:659–701.
- Vettore L, De Sandre G, Di Iorio EE, Winterhalter KH, Lang A, Lehmann H. A new abnormal hemoglobin O Padova, α 30 (B11) Glu→Lys, and a dyserythropoietic anemia with erythroblastic multinuclearity coexisting in the same patient. *Blood* 1974;44:869–77.
- Milner PF, Gooden HM. Rapid citrate-agar electrophoresis in routine screening for hemoglobinopathies using a simple hemolysate. *Am J Clin Pathol* 1975;64:58–64.
- Huisman THJ. The structure and function of normal and abnormal haemoglobins. *Baillieres Clin Haematol* 1993;6:1–30.
- KilinÇc Y, Kumi M, Gurgey A, Altay C, Webber BB, Wilson JB, et al. Hemoglobin O-Padova or α (2)30(B11)Glu→Lys β 2 observed in members of a Turkish family. *Hemoglobin* 1985;9:621–5.
- Schwartz JG. The role of glycohemoglobin and other proteins in diabetes management. *Diabetes Rev* 1995;3:269–87.
- Weykamp CW, Penders TJ, Muskiet FAJ, van der Slik W. Effect of calibration on dispersion of glycohemoglobin values determined by 111 laboratories using 21 methods. *Clin Chem* 1994;40:138–44.
- Goldstein DE, Little RR, Wiedmeyer HM, England JD, Rohlfing CL, Wilke AL. Is glycohemoglobin testing useful in diabetes mellitus? Lessons from the Diabetes Control and Complications Trial. *Clin Chem* 1994;40:1637–40.
- Flückiger R, Harmon W, Meier W, Loo S, Gabbay KH. Hemoglobin carbamylation in uremia. *N Engl J Med* 1981;304:823–7.
- Fantl WJ, Stevens VJ, Peterson CM. Reaction of biologic aldehydes with proteins. *Diabetes* 1982;31:15–21.
- Nathan DM, Francis TB, Palmer JL. Effect of aspirin on determinations of glycosylated hemoglobin. *Clin Chem* 1983;29:466–9.
- Robertson DA, Tunbridge FKE, John WG, Home PD, Alberti KGMM. Diagnostic confusion in diabetes with persistence of fetal haemoglobin. *BMJ* 1992;305:635–7.
- Schnedl WJ, Reisinger EC, Lipp RW, Krejs GJ, Hopmeier P. Hemoglobin variants recently detected in Austria. *Ann Hematology* 1995;71:185–7.
- Aebi-Ochsner CH, Grey VL. Fructosamine measurements in the adult with type I diabetes [letter]. *Diabetes Care* 1995;18:1619–20.
- Schnedl WJ, Reisinger EC, Pieber TR, Lipp RW, Schreiber F, Hopmeier P, et al. Hemoglobin Sherwood Forest detected by high performance liquid chromatography for hemoglobin A_{1c}. *Am J Clin Pathol* 1995;104:444–6.
- Aleyassine H. Low proportions of glycosylated hemoglobin associated with hemoglobin S and hemoglobin C. *Clin Chem* 1979;25:1484–6.
- Turpeinen U, Sipilä I, Anttila P, Karjalainen U, Kuronen B, Kalkkinen N, et al. Two α -chain hemoglobin variants, Hb Broussais and Hb Cemenelum, characterized by cation-exchange HPLC, isoelectric focusing, and peptide sequencing. *Clin Chem* 1995;41:532–6.